Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2019; 47(4): 251-257 | DOI: 10.5543/tkda.2018.27708

Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon

Serhat Sığırcı1, Remzi Sarıkaya2, Kudret Keskin1, Süleyman Sezai Yıldız1, Saadet Pilten Güzel3, Gökhan Çetinkal1, İmran Önur2, Kadriye Orta Kılıçkesmez1
1Department of Cardiology, Sisli Hamidiye Etfal Training and Research Hospital
2Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University
3Department of Biochemistery, Bagcilar Training and Research Hospital


OBJECTIVE
The pathophysiology of the slow coronary flow (SCF) phenomenon is still unclear. The two most frequently cited mechanisms of SCF are endothelial dysfunction and subclinical diffuse atherosclerosis. The aim of this study was to investigate the relation of SCF to serum endocan levels which is associated with endothelial dysfunction and to serum omentin-I levels which is associated with atherosclerosis.

METHODS
A total of 42 patients with SCF and 43 controls with normal coronary flow based on a coronary angiogram were enrolled. Serum endocan and omentin-I levels were measured and the presence of SCF was determined according to Thrombolysis in Myocardial Infarction frame count (TFC) calculations.

RESULTS
The omentin-I level was significantly lower and the endocan level was significantly higher in patients with SCF than in the controls. Receiver operating characteristic curve analysis revealed that the sensitivity and specificity of endocan for SCF was 66% and 70%, respectively (area under the curve [AUC]: 0.760, 95% confidence interval [CI]: 0.65–0.86; p<0.001), and the comparable values for omentin were 66% and 61% (AUC: 0.630, 95% CI: 0.51–0.75; p=0.049). Multivariate logistic regression analysis revealed that a high endocan level (odds ratio [OR]: 6.8, 95% CI: 1.849–2.439, cutoff: 2.45 ng/mL; p=0.003) and a low omentin-I level (OR: 3.6, 95% CI: 1.057–12.893, cutoff: 4.63 ng/mL; p=0.041) were independently associated with the presence of SCF. In patients with SCF, the endocan level was positively correlated with the mean TFC, while the omentin-I level was negatively correlated (r=0.44; p<0.001 and r=-0.22; p=0.049, respectively).

CONCLUSION
These results revealed that endocan and omentin-I might be useful biomarkers for predicting the presence and severity of SCF.

Keywords: endothelial dysfunction, diffuse atherosclerosis, slow flow pathophysiology, adipokine

How to cite this article
Serhat Sığırcı, Remzi Sarıkaya, Kudret Keskin, Süleyman Sezai Yıldız, Saadet Pilten Güzel, Gökhan Çetinkal, İmran Önur, Kadriye Orta Kılıçkesmez. Can biomarkers help us to understand the pathogenesis of coronary slow flow? Endocan and omentin-I in slow coronary flow phenomenon. Turk Kardiyol Dern Ars. 2019; 47(4): 251-257

Corresponding Author: Serhat Sığırcı, Türkiye
© Copyright 2019 Archives of the Turkish Society of Cardiology
LookUs & Online Makale